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In any consideration of the potential impacts of bio­
technology on the food supply, health, safety, and envi­
ronmental impacts are emphasized first. Economic im­
pacts are next, such as societal benefits and costs, the 
organization of production, processing, and distribu­
tion; and firm profitability and market shares.
For both sets of impacts, at issue is how biotechnol­
ogy affects the chain of production and distribution 
running from input manufacturers to producers, proces­
sors, distributors, retailers, and consumers. Food safety 
and nutrition are fascinating because they link health 
and safety concerns with economic concerns. This is be­
cause the economic success of food marketing firms is 
becoming more closely linked to the safety and nutri­
tional attributes of the products they produce and sell. 
This is a key point since the closeness of this link is rela­
tively new.
The focus here is on the marketing level aspects of 
biotechnology, particularly on consumer acceptance 
which will ultimately determine biotechnology’s suc­
cess or failure in the marketplace. This paper operates 
with a premise that sets aside considerations of what 
safety standards government agencies will apply to ac­
ceptance of biotechnology-related products. These con­
siderations, while important and a major topic of dis­
cussion at this conference, are not directly relevant 
to this discussion.
Therefore, it will be assumed that the biotechnol­
ogy-related ingredient, drug, process, or product under 
discussion has been accepted under roughly the same 
government safety standards currently in effect for con­
ventional ingredients, drugs, processes, and products.
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The question then is: How will biotechnology-re­
lated products be marketed? Several earlier presenta­
tions, particularly Carol Tucker Foreman and Kenneth 
Taylor, noted that biotechnology is coming on the 
market in a very specific context, which is the result of consumers’ experi­
ences in the 1980s. This context will be considered first, and then market­
ing issues particular to biotechnology-related products will be discussed.
The Current Food Marketing Environment
In the last decade, increased scientific evidence and consumer awareness of 
links between diet and health have created an expanded market for food 
products that fit specific safety and nutrition profiles. The shift in demand 
coincided with significant changes in the regulatory environment during 
the 1980s. Firms have developed at least two major strategic responses in 
the face of these changes in demand and the regulatory environment 
(Caswell and Johnson, 1990). The first response has been the development 
of strategies that create product or establishment differentiation based on 
food safety and nutrition. The second response has been to develop strate­
gies that attempt to manage any potential liability or exposure to govern­
ment regulation associated with food safety and nutrition issues.
The differentiation-based strategies are domain offensive in nature. 
Firms using them seek to increase or, at a minimum, maintain their market 
shares by emphasizing the food safety and nutrition attributes of their 
products or services. Such differentiation may be based on product charac­
teristics or, in the case of retailers, on the services offered by the firm (e.g., 
screening of fresh produce for pesticide residues). These strategies empha­
size positive information and, where possible, suppress negative informa­
tion. In the current marketing environment, food safety and nutrition 
have become a new basis for non-price rivalry between firms in the food 
system. For example, market shares in the ready-to-eat cereal industry 
have shifted based on the leading firms’ relative success in marketing high 
fiber cereals.
This new emphasis on differentiation and marketing based on food 
safety and nutrition developed in the 1980s because of several factors.
First, as noted above, scientific and consumer knowledge improved and 
consumers subsequently altered their demand for some food products in 
response. Second, the federal government’s policy on health claims made 
by firms on their food labels changed. After 1984, and certainly after 1987, 
such health claims became legal under lenient standards and enforcement
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by the Food and Drug Administration (FDA). This change gave firms a 
much broader scope for effectively communicating differentiation based 
on food safety and nutrition. Third, and at the same time, the Federal 
Trade Commission was lax in pursuing deceptive advertising cases against 
major food products. These latter two factors combined to create a virtual 
free-for-all atmosphere for firms wishing to pursue differentiation strate­
gies.
Fourth, and finally, there was an increased perception among consumers 
in the 1980s that the federal regulatory system was not adequate to insure 
food safety. Many commentators, and several speakers at this conference, 
have implied that this erosion in confidence was the result of hyping of the 
food safety issue by the media and special interest groups. In fact, however, 
the erosion in confidence was due in large part to inadequate government 
regulation during the 1980s, which was documented in a long series of re­
ports (U.S. General Accounting Office 1986a, 1986b, 1989; National Acad­
emy of Sciences, 1987).
Examples of marketing based on food safety and nutrition attributes are 
abundant. Growers and manufacturers have engaged in product innova­
tion to produce frozen foods that meet nutritional recommendations (e.g. 
ConAgra’s Healthy Choice line), baked goods that contain no fat or choles­
terol (e.g., Entenmann’s No-Fat, No-Cholesterol line), and beef products 
produced without use of hormones, antibiotics, feed additives, or preserva­
tives (e.g., Coleman’s Natural Beef). Distributors and retailers have simi­
larly engaged in differentiation by offering services to consumers such as 
in-store nutrition information programs and testing of fresh produce for 
pesticide residues.
The second major strategic response of food firms to changes in demand 
and regulation has been to develop strategies which aim to manage any po­
tential liability associated with food safety and nutri­
tion or attempt to protect the firm from the impacts 
of government regulatory activities. This strategic re­
sponse tends to be defensive in nature and focuses on 
the management of negative attributes and informa­
tion. While often designed to protect specific aspects 
of the firm’s operations, these strategies may also at­
tempt to influence public opinion on the general issue 
of food safety and nutrition, often though repeated 
assurances that the food supply is safe.
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Thus the marketing of biotechnology-related products will take place in 
the context of a market that is sensitized to food safety and nutrition is- • 
sues. It is a market made up of firms and consumers who now have experi­
ence with marketing and differentiation based on food safety and nutrition 
attributes. Biotechnology related products will have to compete not just 
against traditional or conventionally grown products but also against an ar­
ray of products that are sold based specifically on their food safety and nu­
trition characteristics.
Marketing Biotechnology-Related Food Products
A crucial decision facing firms is how to market biotechnology-related food 
products. There appear to be two basic choices. First, firms can treat 
biotechnology related production processes and products as if they were 
just another process or product. In this case, marketing would emphasize 
the positive attributes of the product but not focus on its unique or new 
origins. Second, firms may differentiate the product based on its biotechno­
logical origins. This may work well if the firm has some exclusivity (or at 
least temporary exclusivity) in marketing the product. For example, mar­
keters may be able to stress positive food safety and nutrition attributes re­
sulting from the biotechnological origins of the product, e.g., grown with 
fewer pesticides or containing a higher nutrient content.
But marketers must be aware that even if they prefers the first approach 
events are, at least in the foreseeable future, unlikely to allow a firm to sim­
ply finesse the biotechnology issue. The experience to date with bovine so­
matotropin (BST) bears this out, as will be discussed further below. The dif­
ference in today’s market is that passing a government approval process, 
even when the process is stringent, is no longer enough for the consumer. 
Wishing that it was, is simply howling at the moon at this point in time. As 
several speakers noted yesterday, consumers will evaluate these products 
and the processes with which they were developed based on a range of risk 
and value considerations.
Unfortunately, there appears to be a great deal of resentment in some 
parts of government and the food industry that this is the case. Without 
question, there is ample room for a better understanding of food safety, nu­
trition, and biotechnology among consumers. But this is not a one-way 
street with experts presenting information and “straightening out consum­
ers' perceptions”. To look at the process this way is to take a condescending 
view toward consumers' own safety and value agenda. This agenda may 
not be that of the scientists but it is no less valid.
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As we look to the marketing of biotechnology-related 
food products, there are two major issues. First, again 
assuming that the food product has been approved for 
sale by the government: Who is going to sell 
biotechnology to the public? The candidates are drug 
or ingredient manufacturers, growers or farmers, food
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sociatlons, govern- manufacturers, retailers, trade associations, govern­
ment, or public inter- ment, or public interest groups, 
est groups. The experience to date with BST illustrates the diffi­
culties associated with this question. It is not at all 
clear who will market BST to the public (Richards, 1989a). It appears to 
me, as an outsider, that the introducers and users of BST hoped this was an 
issue they could finesse. In other words, they hoped they could treat BST 
use as just another production process not requiring any special consumer 
marketing program. They have found that in the current marketing envi­
ronment this cannot be done. Several firms are reported to have refused to 
handle milk from cows treated with BST, either entirely or until FDA ap­
proval. These firms include one dairy cooperative (Associated Milk Produc­
ers Inc.), at least three processors (Kraft, Borden, and Ben and Jerry’s 
Homemade Ice Cream), and four retail chains (Safeway, Stop & Shop, 
Kroger, and Van's). In a situation where processors and retailers are increas­
ingly basing major parts of their marketing strategies on food safety and 
nutrition, firms will be very hesitant to risk their hard-earned differentia­
tion by selling products that raise safety concerns while yielding only small 
benefits to themselves. The firms mentioned above apparently found this 
private benefit/cost tradeoff to be negative for BST milk, at least in its ini­
tial period of use.
So, who will sell BST to the public? Supermarkets complain that the 
makers of BST are dumping the responsibility for allaying consumer fears 
regarding BST on them. An official of the Kroger Co., for example, is 
quoted as saying, “If they think it's safe, let them step up the plate and de­
fend it" (Richards, 1989b) and, “If we’re going to make any mistakes on 
this, we’re going to make them on the side of safety” (Ingersoll, 1989). The 
firms’ differentiation strategies make them reluctant to accept any risks to 
their reputations that might be associated with marketing biotechnology- 
related products that have not already been broadly accepted by the public.
The second major marketing issue facing biotechnology-related prod­
ucts is: What information disclosure will be required in the presentation of
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In marketing, the the products? And, in addition: Who (federal or state
biotechnology issue government) will require this information? Labeling 
can not be simply fi- . . . .  ,
n8ssad is an attractive option in the current market atmo­
sphere of increased consumer awareness because it is 
responsive to consumers’ desire for control. It is also 
attractive to regulators who wish to place more reliance on markets rather 
than government agencies for making choices regarding food safety and 
nutrition.
We are, I think, groping for a policy on when provision of information 
through labels is a desirable regulatory strategy. Many firms have not pre­
sented a consistent front on this issue. If firms believe that more informa­
tion is better for the consumer in the area of health claims, can they in 
good faith object to the labeling of biotechnology-related products? My 
prediction is that for controversial biotechnology-related products, label­
ing will be widespread. Either government units will require labeling to 
identify such products or some firms will voluntarily label that they do 
not use any biotechnology-related processes or ingredients in their prod­
ucts. In either case, consumers are likely to be able to identify products 
that are biotechnology-related from those that are not. Again, in market­
ing, the biotechnology issue cannot be simply finessed.
The key question, ultimately, is how biotechnology-related products 
will compete in a marketplace made up of traditional and conventionally 
processed products and those that are being marketed specifically on the 
basis of food safety and nutrition attribute. This is a clouded question at 
this point in time.
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